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Background: Glycosylation is increasingly recognized as one of the most relevant postranslational modiﬁcations.
Sialic acids are negatively charged sugars which frequently terminate the carbohydrate chains of glycoproteins
and glycolipids. The addition of sialic acids is mediated by sialyltransferases, a family of glycosyltransferases
with a crucial role in cancer progression.
Scope of the review: To describe the phenotypic and clinical implications of altered expression of sialyltransferases
and of their cognate sialylated structures in cancer. To propose a unifying model of the role of sialyltransferases
and sialylated structures on cancer progression.
Major conclusions:We ﬁrst discuss the biosynthesis and the role played by themajor cancer-associated sialylated
structures, including Thomsen–Friedenreich-associated antigens, sialyl Lewis antigens, α2,6-sialylated
lactosamine, polysialic acid and gangliosides. Then, we show that altered sialyltransferase expression in cancer,
consequence of genetic and epigenetic alterations, generates a ﬂow of information toward the membrane
through the biosynthesis of aberrantly sialylated molecules (inside-out signaling). In turn, the presence of aber-
rantly sialylated structures on cell membrane receptors generates a ﬂow of information toward the nucleus,
which can exacerbate the neoplastic phenotype (outside-in signaling). We provide examples of self-fueling
loops generated by these ﬂows of information.
General signiﬁcance: Sialyltransferases have a wide impact on the biology of cancer and can be the target of
innovative therapies. Our uniﬁed view provides a conceptual framework to understand the impact of altered
glycosylation in cancer.© 2014 Published by Elsevier B.V.L, acute myeloblastic leukemia;
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51 2094746.1. Introduction
The sugar portions of glycoproteins and glycolipids are often termi-
nated by sialic acids (Sia): sugars which, owing to their negative electric
charge, are crucial in regulating molecular and cellular interactions
[1–3]. Sialic acids can be linked to subterminal sugars through an α2-
6-bond to N-acetylgalactosamine (GalNAc) or N-acetylglucosamine
(GlcNAc); an α2,3 or α2,6 bond to galactose (Gal) or through a α2-8-
bond to another sialic acid, forming polysialic acids. Sialyltransferases
are a class of glycosyltransferases which catalyze the transfer of sialic
acid from a common donor substrate (CMP-sialic acid) to a carbohy-
drate chain. Sialyltransferases show a certain degree of redundancy, in
that the same glycosidic linkage can often be elaborated by different
gene products [4] and are crucially involved in cancer progression [5,
6]. In this reviewwehave summarized the studies showing the intimate
relationship between sialyltransferases and their products with the
mechanisms of cell transformation and cancer progression. In particu-
lar, we provide examples of how the signaling generated by sialylated
molecules at the cell membrane can activate self-ampliﬁcation loops
fueling cancer growth.
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Early studies indicated that the level of sialyltransferase activity is
often increased in plasma of cancer patients [7–10] and that the extent
of sialylation of cancer cells is associated with their invasive proper-
ties [9,11–18]. Former functional studies on the overall effect of sialic
acids in cancer biology, using sialidases or sialyltransferase inhibitors
sometimes provided contradictory results [19]. For example, the effect
of sialidase treatment on collagen IV adhesion was the opposite in
murine and human cancer cells [13,14], while sialic acid depletion by
the sialyltransferase inhibitor KI-8110 reduced metastasis formation
[20] without affecting cell adhesion to extracellular matrix glycopro-
teins but rather decreasing platelet aggregation [16]. According to
other studies, the inhibition of sialic acid incorporation by different
compounds impaired adhesion, migration, in vivo tumor growth and
metastasis formation [21–25].
3. Sialylated structures involved in cancer progression
In this section we describe the structure and biosynthesis of speciﬁc
sialylated structures and discuss their contribution to cancer biology
and progression.
3.1. Thomsen–Friedenreich (TF)-related antigens
Antigens T, Tn and their sialylated variants sialyl-T (sT) and sialyl-Tn
(sTn) are small cancer-associated O-linked structures, often referred to
as Thomsen–Friedenreich (TF)-related antigens [26], whose structure
and biosynthesis are depicted in Fig. 1.
In breast cancer, mucin glycosylation undergoes a characteristic
switch from the expression of core 2 structures to the accumulation of
T [27] and sTn structures [28,29]. This change is accompanied by a con-
comitant and apparently paradoxical up-regulation of sialyltransferase
ST3GAL1 [30], which converts T in sialyl-T (sT) antigen [31], inhibiting
the synthesis of core-2 based structures [32]. ST3GAL1 over-
expression in breast cancer is associated with conditions characterizing
tumor growth, such as the presence of the inﬂammatory enzymeGalNAc-O-Ser/Thr
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Fig. 1. Structure and biosynthesis of Thomsen–Friedenreich-related antigens. The Tn antigen, or
can be transformed in sialyl-Tn antigen by the action of ST6GALNAC1 or can be elongated by t
addition of a β1-3GlcNAc, yielding the core 3 structure. The T antigen can be further processe
by the addition of sialic acid inα2-3-linkage to Gal, mainly by ST3GAL1, yielding the sialyl-T ant
or ST6GALNAC2, yielding s6T antigen.cicloxygenase-2 (COX-2) and of its product prostaglandin E2 (PGE2)
[33] and hypoxia [34]. On the other hand, the expression of the cell
membrane mucin 1 (MUC1), which is frequently altered in cancer
[35], down-regulates ST3GAL1 expression in mouse mammary carcino-
ma cells [36]. Constitutive ST3GAL1 expression by murine mammary
epithelium contributes to breast cancer progression. In fact, in PyMT
mice, which spontaneously develop breast cancer, the concomitant
over-expression of ST3GAL1 inmammary glands results in the develop-
ment of mammary tumors with shorter latency, although no accumula-
tion of sT antigenwas observed [37]. Altogether, these data suggest that
the biological effect of ST3GAL1 on cancer progression might not be
dependent on the synthesis of its cognate carbohydrate antigen, but
rather on its proposed tumor promoter activity [37]. A paradoxical
over-expression of both T antigen [38] and sialyltransferases ST3GAL1
and ST3GAL2 [39] has also been reported in colon cancer, with the
former associated with lymph node metastasis [39]. In bladder cancer
tissues ST3GAL1 mRNA was also elevated, particularly in patients with
tendency to recurrence [40].
sTn, a pan-carcinoma antigen expressed by many malignancies
[41–45], is usually associated with a worse prognosis [46]. The biosyn-
thesis of sTn largely depends on sialyltransferase ST6GALNAC1, while
the contribution of ST6GALNAC2 appears to be negligible [47,48],
being more speciﬁc for s6T biosynthesis. However, the reduced O-
acetylation of sialic acid [49] and the down-regulation of the competing
core 1 galactosyltransferase [50,51] also contribute to increased sTn ex-
pression in cancer [52]. In bladder cancer, sTn is expressed by 75% of
high-grade tumors and correlates with ST6GALNAC1 expression [45].
Moreover, the expression of this carbohydrate antigen, associated
with s6T, is a marker of disease-free survival and predicts response to
immunotherapy with bacillus Calmette–Guerin (BCG) [45]. In different
cancer cell lines, the phenotypic effects of sTn over-expression obtained
by forcing ST6GALNAC1 expression, are multiple and only partially
overlapping. These include: morphological changes and reduced ability
tomigrate on extracellularmatrix (ECM) components [53], reduced cell
adhesion and increased cell migration [54–56], increased metastatic
ability [57], decreased intercellular aggregation and increased ECM ad-
hesion,migration and invasion [58], increased cell motility and invasion/Thr
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growth in vivo involves the interaction with Siglec 15, a member of
the Siglec family of sialic acid binding lectins [59], expressed by macro-
phages. sTn binding by the tumor-associated macrophages, which
usually display an immunosuppressive M2 phenotype, triggers TGF-β
release, establishing a microenvironment favoring cancer growth [60].
The ability of sTn-expressing cells to induce a tolerogenic phenotype
of innate immune cells has recently been observed in a different
model system [61].
Expression of ST6GALNAC2 displays opposite effects in colon and
breast cancer. In colon cancer it is associatedwith lymph-nodemetasta-
sis and poor survival [39], while in breast cancer it suppresses
brain metastases [62]. The latter effect is due to the replacement of
the T antigen with s6T with the consequent block of the binding of
galectin-3 to membrane glycoconjugates, a key step in brain metastasis
formation [62].
3.2. Sialyl Lewis antigens
Sialyl Lewisa (sLea) and sialyl Lewisx (sLex) are type 1 or type 2
fucosylated antigens terminated by α2,3-linked sialic acid [63], whose
structure and biosynthesis are depicted in Fig. 2. Their relevance in can-
cer mainly originates from their binding to E- and P-selectins expressed
on activated endothelial cells [64]. The ectopic expression of sLe antigens
by cancer cells allows the adhesion to endothelial cells, promoting
metastasis [65], tumor growth and angiogenesis [66]. ExperimentalGlcNAc -R
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Fig. 2. Structure and biosynthesis of sialy Lewis antigens and Sia6LacNAc. Substitution of
GlcNAc by aβ1,3-linked galactose leads to the basic unit of type 1 chain,while substitution
with a β1,4-linked galactose leads to lactosamine, the basic unit of type 2 chains. α2,3-
sialylation of type 1 or 2 chains by the indicated sialyltransferases forms the substrates
for the successive addition of fucose, which is mediated by FUT3 in sLea biosynthesis
and by FUT3, -4, -5, -6, or -7 in sLex biosynthesis. The α2,6-sialylation of type 2 chains
by ST6GAL1 leads to the formation of Sia6LacNAc.manipulation of α2,3-sialyltransferases [67–72] and/or α1,3/4
fucosyltransferases [73–75] indicates that both enzymes classes can
determine the level of sLe biosynthesis, even though this does not neces-
sarily imply a regulatory role in vivo for those enzymes. Studies onmRNA
expression of sialyltransferases in clinical specimens had reported par-
tially conﬂicting conclusions [76–78]. The lack of a clear relationship be-
tween sialyl-/fucosyltransferase modulation and sLe expression in colon
cancer [76] suggests that in this malignancy, the de novo expression of
sLe antigens might be due to other mechanisms (reviewed in [79,80]).
TNF-α stimulates the expression of selectin ligands through different
mechanisms: in lung cells through stimulation of ST3GAL4 [72,81], in
prostate cancer cells through up-regulation of ST3GAL3 and other
glycosyltransferases [82]. Epithelial to mesenchymal transition (EMT),
a crucial event in metastasis formation of epithelial tumors, induced
by EGF or bFGF treatment of colon cancer cells, produced expression
of sLex/sLea antigens [83] through the transcriptional activation
of sialyltransferases ST3GAL1, -3- and -4 (and of FUT3), mediated by
c-myc [83]. The transcription of ST3GAL6, also involved in sLex biosyn-
thesis, is increased by treatment with 5-aza-2′-deoxycytidine, a drug
which inhibits DNAmethylation [84]. It is likely that the altered pattern
of methylation of tumors inﬂuences the expression level of
sialyltransferases involved in the biosynthesis of sialylated tumor anti-
gens. In breast cancer, high ST3GAL3 mRNA expression, together with
low ST6GAL1, are associated with worse prognosis [85,86]. Breast can-
cers are grouped according to the expression of the estrogen receptors
(ER). The privileged expression of sLex by ER-negative tumors is
consistent with the over-expression of a group of glycosyltransferases,
including ST3GAL6, FUT3, and FUT4 [87]. Although expression of sLex
is not directly associated with survival, patients displaying a double
sLex/ER positive phenotype are at higher risk of metastasis to bone
where E-selectin, the countereceptor of sLex, is constitutively expressed
[87].
3.3. Polysialic acid
Long linear arrays of sialic acid residues joined through an α2-8-
linkage which decorate the N-linked chains of the neural cell adhesion
molecule (N-CAM) [88] and of a few other glycoproteins are referred
to as polysialic acid (PSA). The biological properties of PSA depend on
the degree of polymerization (DP), which is high in embryonic and
fetal brain but low in the adult [89]. High DP PSA exerts a strong inhib-
itory effect on intercellular adhesion [90,91], allowing the tissue plastic-
ity which characterizes immature nervous system. PSA regulates both
homophilic interactions between N-CAM molecules and heterophilic
interactions between N-CAM and other cell adhesion molecules
[92]. The biosynthesis of PSA is mediated by two sialyltransferases,
ST8SIA2 (also known as STX) [93] and ST8SIA4 (also known as PST)
[94], which display only partially overlapping properties in that only
ST8SIA2 is dependent on development while ST8SIA4 synthesizes
longer PSA chains [95].
High DP PSA is re-expressed in a variety of human cancers [96]
mainly, but not exclusively, of neuroectodermal origin [97,98] and is
usually associated with malignancy. In a seminal study on neuroblasto-
ma cells, the DP of PSAwas found to be greater than 55 [99]. In vitro, the
presence of PSA increased cell growth andmigration [100,101], while in
immunodeﬁcient mice PSA expression facilitated the growth of glioma
cells in the brain [102] and increased metastasis formation [103], al-
though it reduced the subcutaneous growth of lung cancer cells in
nude mice [104]. The increased cell motility associated with high DP
PSA can be explained by at least two differentmechanisms: through de-
creased E-cadherin-mediated intercellular aggregation [92] and by de-
creased number of cell-substratum focal adhesions [105]. The
contribution of the two polysialyltransferases to PSA re-expression is
tissue-dependent [98,102,106]. Bone marrow detection of ST8SIA2
mRNA in neuroblastoma patients predicts metastatic progression
[107]. The therapeutic inhibition of PSA biosynthesis has been pursued
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are expressed without a concomitant expression of PSA [104], because
of the lack of N-CAM. Even though PSA has been associated withmalig-
nancy, N-CAM expression is associated with reduced invasion [109,
110]. This could explain why the concomitant transfection of lung ade-
nocarcinoma cells with both polysialyltransferases and N-CAM cDNAs
reduced in vivo growth [104]. Consistently, although neuroblastoma pa-
tients with higher levels of polysialylated N-CAM presented more often
metastasis at diagnosis, those without polysialylated N-CAMhad a poor
ﬁve year survival [111].
3.4. Sia6LacNAc
The transfer ofα2,6-linked sialic acid to lactosaminic chains (Fig. 2),
mediated by β-galactoside α2,6-sialyltransferase (ST6GAL1) generates
α2,6-sialylated lactosamine (Sia6LacNAc). Lectins from Sambucus
nigra (SNA), Trichosanthes japonica [112] or Polysporus squamosus
[113] have beenwidely used to detect Sia6LacNAc in normal and cancer
tissues. The fucosylated variant of Sia6LacNAc recognized by antibody
ST2H [114] and the CDw75 antigen [115] are also the product of
ST6GAL1. Although widely expressed by normal tissues ST6GAL1 is a
cancer-associated glycosyltransferase. After the ﬁrst description of
ST6GAL1 elevation in colon cancer tissues [116], successively conﬁrmed
by several groups [117–119], the enzyme and/or its product was found
to be increased in a variety of malignancies (reviewed in [5,120]), as re-
ported in Table 1. In colon cancer, increased SNA reactivity [121] and
ST6GAL1 expression [122] have been reported to be predictive markersTable 1
Human cancers displaying elevated ST6GAL1 and/or Sia6LacNAc.
Tissue of origin Enzyme protein mRNA Sia6LacNA
Colon Activitya – –
– – SNA
Activity – –
Activity – SNA
– PCR –
Mabb – –
Mab – –
– – SNA
– – T. japonic
Activity PCR SNA
– PCR –
Activity – Anti CDw
– – SNA
– – SNA
Activity – –
Stomach – PCR –
Activity PCR –
– – Anti CDw
AMLc Activity – –
ALLd – PCR CD22e
Choriocarcinoma Activity PCR –
Cervix – PCR –
– PCR –
Ovary – PCR –
Brain Polyclonal Ab Northern SNA
Liver Mab – CD22
Activity PCR, i.s. hybf SNA
– PCR Anti CDw
– – Viscumin
Activity – –
Breast – PCR –
– – Anti CDw
Mouth Activity – SNA
Activity – SNA
Cutaneous cancers Mab – –
a ST6GAL1 expression has been measured as enzyme activity.
b ST6GAL1 expression has been measured with a monoclonal antibody.
c AML: acute myeloblastic leukemia.
d ALL acute lymphocytic leukemia.
e Sia6LacNAc has been detected using a soluble form of the Sia6LacNAc-speciﬁc siglec CD22
f In situ hybridization.of poor prognosis. Colon cancers can be grouped according to two main
transformation pathways. The majority display inactivation of the APC
gene, mutation of K-ras and other changes. These cases usually show
chromosomal instability (CIN) but microsatellite stability (MSS). The
minority of the cases shows the inactivation of DNA repair genes,
resulting in microsatellite instability (MSI), and a consequent inactiva-
tion of crucial tumor suppressor genes. The increased SNA reactivity of
colon cancer cases is mainly associated with the MSS phenotype [123],
probably because of the known dependence of ST6GAL1 on Ras activa-
tion (see Section 5.1), a key event in MSS progression.
While in rodent hepatoma ST6GAL1 was elevated [124,125], among
liver cancer patients only a small group displayed increased ST6GAL1
expression [126,127], while the few patients with decreased expres-
sion [126] showed poor differentiation and prognosis [128]. Also in
breast cancer, increased ST6GAL1 expression was displayed only by a
group of patients, mainly of grade III [85].
An association between α2,6-sialylation and invasive growth was
suggested by early studies [129–131]. However, to study the functional
implications of the overexpression of ST6GAL1 and/or its cognate
Sia6LacNAc structures, we [132] and successively others [133–135] ob-
tained stable ST6GAL1 transfectants in different cell lines. Thesemodels
showed increased α2,6-sialylation of β1-integrins and increased bind-
ing to extracellular substrates in epithelial cancers [133,134,136–138].
The α2,6-sialylation of β1-integrins modulates intracellular signaling
(as described in Section 5.2) and is involved in a self-fueling loop (as
described in Section 5.3). In addition, α2,6-sialylation of β1-integrins
can reduce the binding of galectin-3 [139] a lectin which, in somec References Remarks
[116]
[236,237] Low reactivity in adenomas
[118] Increased in metastasis
[238]
[77] Detected in metastasis
[119]
[122] Worse prognosis
[121] Worse prognosis
a [112] Only differentiated carcinomas
[239]
[76]
75 [117]
[123] Reactivity mainly in MSS cases
[240] Increased reactivity of some plasma proteins
[241]
[242]
[243] Associated with local recurrence
75 [244] Worse prognosis
[245] Increased in blasts
[170] Increased mRNA and Sia6LacNAc structures
[246]
[247–249]
[250]
[251]
[252] Increased only in non-neuroectodermal tumors
[127]
[126] Increased in a minority of cases
75, Sia6LacNAc gangliosides slightly increased
[253] ST6GAL1 mRNA unchanged
[128] Decreased activity correlates with poor prognosis
[85] Associated with grade III
75 [254]
[255]
[256] Detected in serum
[257] Associated with invasion
.
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prevention of apoptotic death and increased malignancy. However,
ST6GAL1 expression reduced the tumorigenic potential and the multi-
layer growth of the colon cancer cell line SW948 [137] and the invasive
growth of glioma cells [135,141–143]. Mammary tumors developed by
PyMT mice (Section 3.1) in a ST6GAL1-null background displayed in-
creased differentiation but the same growth rate as those grown in
the PyMT mice expressing ST6GAL1 [144], although ST6GAL1-negative
tumors exhibited altered expression of genes associated with focal ad-
hesion signaling and had decreased phosphorylation of focal adhesion
kinase, a downstream target of β1-integrins. The ST6GAL1 protein has
been reported to be associatedwith the stem phenotype of both normal
and cancer cells [145]. As detailed in Section 5.2, ST6GAL1-mediated
sialylation prevents VEGF-independent angiogenesis [146,147]. Associ-
ation of ST6GAL1 with radiation resistance and with drug resistance is
discussed in Section 4. Altogether, these data indicate that the relation-
ship between Sia6LacNAc and invasive growth is complex and probably
strongly cell- and tissue-dependent.3.5. Gangliosides
Gangliosides are sialic acid-containing glycosphingolipids, whose
expression is often deranged in cancer. The two sialyltransferases
which mainly control ganglioside biosynthesis are ST3GAL5 (GM3
synthase) which synthesizes GM3, precursor of all ganglio-series glyco-
lipids, and ST8SIA1 (GD3 synthase)which synthesizes GD3, precursor of
b-series gangliosides (Fig. 3). In general, it appears that malignancy is
positively associated with the expression of GD3 [63,148,149] and neg-
atively with that of GM3 [150–153]. A high level of GD3 characterizes
melanoma, while neuroblastoma typically exhibit a high GD2/GD3
ratio, owing to high levels of B4GALNT1 (GD2 synthase) [154]. Neuro-
blastoma cells grown as nude mice xenografts express higher levels of
ST8SIA1 and of b-series gangliosides [155], while knock-down of
ST8SIA1 by antisense vector inhibited tumor growth and angiogenesis
[156–158]. Enhanced malignancy in ST8SIA1-expressing cells can be
due to interaction of GD3 or GD2with integrins [159], growth factor re-
ceptors [160–162] and Src kinases [163] (Fig. 4) (discussed in detail in
Section 5.2). A recent study [164] reports that ganglioside GD2 is a
marker of breast cancer stem cells and that ST8SIA1 is a crucial regulatorGal 1,4Glc-Cer
GalNAc 1,4Gal 1,4Glc-C
Sia 2,3
Lactosylceramide GM3
GM2
ST3GAL5
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Fig. 3. Simpliﬁed representation of ganglioside biosynthesis. A: sialylation of lactosylceramide
addition of a second, α2-8-linked sialic acid by ST8SIA1, yields GD3, which is the ﬁrst memb
GD2 synthase) yields GM2 and GD2, respectively. B: biosynthesis of the brain metastasis-assocof GD2 expression. In this tumor, ST8SIA1 is regulated by NFkB and
estradiol [165] (see Section 5.1). In considering the phenotypic effects
of ST8SIA1 expression it should be considered that this enzyme alsopro-
vides the basis for the biosynthesis of more complex gangliosides, such
as GQ3 and GP3 [166]. A therapeutic approach of lung cancer based on
ST8SIA1 suppression by RNA interference has been proposed [149].
The growth inhibitory effects of GM3 are supported by several ob-
servations. First, the growth-suppressing activity of GM3 is so strong
that it can normalize the neoplastic phenotype induced by the expres-
sion of the viral oncogene v-Jun in ﬁbroblasts [150] (Fig. 5); second,
the expression of GM3 can induce cell death [167]; third, ﬁbroblasts
from ST3GAL5-KO mice, lacking a- and b-series gangliosides, show
MAPK activation [168], indicating that the mere absence of GM3 even
in the absence of GD3 is sufﬁcient to activate theMAPK pathway. How-
ever, in oncogene-transformed cells a near complete ganglioside deple-
tion results in a dramatic inhibition of in vivo growth in syngeneic
animals [169]. Although ST3GAL5 and GM3 are usually associated
with reducedmalignancy, some observations suggest the opposite rela-
tionship [170–173]. The association between malignancy and ST8SIA1/
GD3 also presents some exceptions [174–176].
Sialyltransferases involved in the biosynthesis ofmore complex gan-
gliosides are prominently involved in some cancers. ST6GALNAC5,
which synthesizes GD1α (Fig. 3), is a crucial mediator of breast cancer
metastasis to the brain [177] because the ectopic expression by breast
cancer cells of this enzyme,which is normally restricted to the brain, en-
hances their adhesion to brain endothelial cells and their passage
through the blood–brain barrier. In other malignancies ST6GALNAC5
plays an opposite role. In fact, the CpG islands of its promoter are fre-
quently hypermethylated in colon adenomas and carcinomas [178]
while its over-expression in glioma cells lead to reduced malignancy
[179]. The expression of ST6GALNAC6, another sialyltransferase in-
volved in the biosynthesis of higher disialogangliosides, also shows
down-regulation in cancer [180].4. Sialyltransferases in resistance to chemotherapy and radiotherapy
Resistance to radio- and chemotherapywhich are, beside surgery, the
most widely used cancer therapies is a major reason of cancer death. A
role of sialyltransferases in causing resistance to these treatments iser
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sistance to ovarian cancer cells [181] and leukemia cells [182], while in a
colon cancer cell line it reduces sensitivity to the EGFR kinase-speciﬁc in-
hibitor geﬁtinib [183]. On the other hand, human T cell lymphoblastic
leukemia cells resistant to the drug desoxyepothilone B displayed
reduced expression of ST6GAL1 [184]. Sialyltransferase ST8SIA4 is one
of the glycosyltransferases over-expressed in a drug-resistant variant of
the erythroleukemia cell line K562 [185] and in multidrug resistant
variants of acute myeloid leukemia cells [182]. These changes affect
expression of P-glycoprotein and of multidrug resistance-related protein
1 through modulation of PI3K/Akt signaling. Interestingly, Akt activation
appears to be at the basis of ST6GAL1 and ST8SIA2 induced
chemoresistance in hepatocarcinoma cell lines [186].
ST6GAL1 is also crucially involved in radiation resistance. In fact, ex-
posure to ionizing radiations resulted in increased expression of
ST6GAL1 in animal tissues and cultured cell lines [187,188],while forced
expression of ST6GAL1 cDNA in colon cancer cell lines induced radiation
resistance [188]. The increased signaling through α2,6-sialylated β1-
integrins results in activation of paxillin and Akt signaling [189,190],
promoting cell survival [191].5. Cancer associated glycans and signaling pathways
Neoplastic transformation is usually due to altered regulation of
genes regulating cell growth (oncogenes and tumor-suppressor
genes). The carbohydrate structures described above are aberrantly
expressed in cancer mainly because genetic and epigenetic changes
alter oncogene/tumor suppressor gene regulation which, in turn,
perturbs glycosyltransferase expression. Through the synthesis of
cancer-associated carbohydrate structures, this generates a ﬂow of in-
formation from the nucleus to the cell surface (inside-out signaling).
On the other hand, membrane molecules decorated by cancer-
associated glycans convey aberrant signaling pathways targeting gene
expression, generating an information ﬂow from the cell membrane tothe nucleus (outside-in signaling). In some cases, these bi-directional
information ﬂows form self-fueling loops, as shown in Fig. 5.5.1. Inside-out signaling: genetic and epigenetic changes leading to
sialyltransferase modulation
ST6GAL1 provides a very good example of a glycosyltransferase
which is directly controlled by an oncogene. The positive effect of Ras
signaling on ST6GAL1 expression has been known since the '90s
[192–194]. More recently, it has been shown that both oncogenic N-
ras andH-ras stimulate ST6GAL1 transcription throughRalGEF signaling
[195] and that in a colonocyte cell line Ras drives theα2,6-sialylation of
β1-integrins through ST6GAL1 over-expression [136]. Consistently,
ST6GAL1 shows negative regulation by the tumor suppressor transcrip-
tion factor RUNX3 [196]. On the other hand, it has been reported that
ST6GAL1 expression is stimulated by caveolin-1 [197] a gene with a
prevalent tumor suppressor activity.
Transfection of medulloblastoma cells with the muscle-speciﬁc
transcription factor Pax3 induces polysialylation of N-CAM through
increased expression of ST8SIA2 but not of ST8SIA4 [198].
Sialyltransferases display modulation by estrogens. Estradiol stimu-
lates ST3GAL3but inhibits ST6GAL1 in breast cancer cells [199]. The core
promoter of ST8SIA1 contains two putative estrogen response elements
(ERE) to which the transcription factor NFkB binds, stimulating
transcription of ST8SIA1 [200]. However, in ER-positive breast cancer
cells estradiol binding to ERE inhibits NFkB binding, resulting in
down-regulation of ST8SIA1 transcription [165] and explaining the
up-regulation of ST8SIA1 transcription in ER-negative breast cancers.
Interestingly, in prostate carcinoma cells NFkB positively regulates
the transcription of sialyltransferases ST3GAL1, -2 and -6 [201].
Sialyltransferases ST3GAL1, -3 and -4 are down-regulated by
the metastasis-suppressor gene nm23-H1 [202] but are up-regulated
by c-myc [83]. Although in porcine kidney cells, ST3GAL1 is transcrip-
tionally regulated by TGF-β/SMAD3 signaling [203], in a human colon
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out affecting the mRNA levels of known sialyltransferases [204].
Treatment of HCT15 colon cancer cells with the demethylating drug
5-azacytidine (5-AZA) activates ST3GAL6 and expression of sLex on
MUC1 [84], while in prostate cancer cells, androgens induce transcrip-
tional activation of ST3GAL2 through demethylation of its promoter
[205].
5.2. How the expression of sialylated glycans on the cell membrane signals
to cell interior (outside-in signaling)
The lipid rafts are cholesterol-rich membrane microdomains in
which growth factor receptors, integrins and gangliosides coexist, favor-
ing their interactions. The sialylation of plasma membrane glycopro-
teins, including integrins and growth factor receptors, modulates their
activity and consequently the origin of the signaling pathways toward
the nucleus (outside-in signaling). In addition, the activity of these
receptors can be indirectly modulated by gangliosides. Examples of
these mechanisms, depicted in Fig. 4, are described below.
c-Met is the receptor of the hepatocyte growth factor (also known as
scatter factor) and is crucial for cancer cellmotility andmetastasis [206].
In a breast cancer cell line, the constitutive expression of ST8SIA1 and of
gangliosides GD3 and GD2 results in proliferation in the absence of
serum [161,162] because of the constitutive activation of c-Met [160]
and in the stimulation of MAPK and PIP3 signaling [160]. On the otherhand, interaction of c-Met with monosialogangliosides GM3 and
GM2 resulted in inhibition of its signaling and of cell motility
[207–209]. c-Met activation can also be induced by the ST3GAL4-
induced expression of sLex, leading to phosphorylation of FAK and Src
proteins [70]. Thus, the activation of c-Met signaling is the common
downstream effect of the expression of different sialyltransferases.
GD3 can also stimulate cancer cell growth by direct interaction with
cell signal transducers located on the internal side of the plasma mem-
brane. GD3 promotes the association between FAK and p130 [210,211],
enhancing signaling [212,213] because of a stronger involvement of the
Src kinase family member Yes which, in GD3-expressing cells, localizes
in raft domains even before serum treatment [163]. The negative effect
of ganglioside GM3 on the cell growth and on the activity of growth fac-
tor receptors has long been known [214,215]. A large body of data
points to the interaction between GM3 and the ERBB membrane recep-
tors family [216]. GM3 interacts with the GlcNAc termini of N-linked
chains of ERBB1 (EGF receptor, EGFR), inhibiting its ligand-dependent
activation [217–220], while the interaction of GM3 with the EGFR/
ERBB2 heterodimer induces its retention in lipid rafts in a phosphorylat-
ed form [221–223]. The expression of ST3GAL5 and of GM3 in non small
cell lung cancer results in an increased number of EGFR molecules and
increased sensitivity to the EGFR-tyrosine kinase geﬁtinib [224]. It has
been proposed that the GM3-mediated inhibition of EGFR signaling is
due to the inhibitory activity of protein kinase C-α on EGFR [225]. On
the other hand, normal human ﬁbroblasts not expressing ST3GAL5
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itant strong inhibition of EGFR signaling [226]. GM3 inhibits the pro-
angiogenic activity of VEGF [152] through direct interaction with the
VEGFR-2 receptor [227]. Apart from ganglioside contribution, glycosyl-
ation of EGFR can directly modulate its activity. In a lung cancer
model, sialylation and fucosylation of EGFR resulted in a reduced, rather
than increased, tendency to receptor dimerization and phosphorylation
after EGF binding [228]. Consistently, in a colon cancer cell line, inhibi-
tion of ST6GAL1 resulted in increased growth and EGFR signaling
upon EGF binding and increased sensitivity to the EGFR inhibitor
geﬁtinib [183]. An opposite effectwas displayed by ST3GAL1, whose ex-
pression enhanced geﬁtinib sensitivity [224]. However,α2,6-sialylation
can also indirectly stimulate ERBB2/ERBB3 signaling. In fact, inhibition
of ST6GAL1 by miR-199a reduced sialylation and the expression of a
tumor suppressor which inhibits ERBB2/ERBB3 signaling [229].
Integrins are heterodimeric membrane glycoproteins mainly in-
volved in binding to extracellular matrix components. After binding,
integrins form focal adhesion complexes, activating signal transduction
pathways downstream of growth factor receptors (Fig. 4). The integrin/
growth factor receptor crosstalk provides the cells with environmental
signals necessary for proliferation [230,231]. The ST6GAL1-mediated
sialylation of integrin β1-chains reinforces the integrin-based signal
transduction, as shown by increased binding of talin [134] and phos-
phorylation of focal adhesion kinase [144] and provides a survival signal
through activation of paxillin/Akt [190]. Integrin function can also be
modulated by interactions with the sugar portions of gangliosides. In
fact, gangliosides GD3 and GT1b inhibit the binding of α5β1 integrin
to ﬁbronectin by direct binding of their carbohydrate portion with
that of integrin α5 subunit [159] while GM3, in association with
tetraspanin and CD9 interacts with β1 integrins and inhibits cell
motility [232,233].
Induction of tumor angiogenesis is mainly regulated by VEGF-
mediated stimulation of VEGF receptors. Inhibition of this interaction
by the anti-VEGF-A monoclonal antibody bavacizumab is a widely
used anti-cancer therapy. However, the existence of a glycosylation-
dependent, VEGF-independent mechanism of VEGFR stimulation,
which can be at the basis of bevacizumab resistance has been recently
described [146,147]. According to this mechanisms, in the tumor
hypoxic conditions exacerbated by anti angiogenic treatment, ST6GAL1
was down-regulated, while N-acetylglucosaminyltransferase-V (MGAT5,
responsible for β1,6-branching)was up-regulated. The coordinatemodu-
lation of the two enzymes leads to a remodeling of the N-linked chains of
VEGFR2 which favors its binding by galectin-1 which, in turn, results in
VEGFR signaling in the absence of its ligand. Thus, the ST6GAL1-
mediated sialylation of VEGF receptors exerts a key role in preventing
angiogenesis and tumor progression [146,147].
N-CAM provides another example of a cell adhesionmoleculewhich
modulates intracellular signaling through its PSA chains. Removal of
PSA from N-CAM of neuroblastoma cells activates extracellular signal-
regulated kinase (ERK), leading to reduced proliferation and neuronal
differentiation [234].
5.3. Inside-out/outside-in loops
Examples of positive or negative inside-out/outside-in loops are pro-
vided in Fig. 5. In the positive loop shown in A, a Ras mutation activates
ST6GAL1, leading toα2,6-sialylation of β1 integrins, stronger binding to
ECM and increased FAK signaling. In the negative loop shown in B, cell
transformation by the viral oncogene v-jun inhibits sialyltransferase
ST3GAL5 and ganglioside GM3 expression, resulting in increased
growth rate and anchorage independent growth [150]. Forced expres-
sion of ST3GAL5 results in the normalization of the transformed pheno-
type [150]. These data provide proof of the principle that aberrant
oncogene expression results often in a deranged glycosylation pattern
(inside-out), which in turn, modiﬁes the gene expression of cancer
cells (outside-in).6. Concluding remarks
Glycosylation, among other postransductional modiﬁcations, is in-
creasingly appreciated as a tool through which nature modiﬁes the
functional properties of the molecules without the need to alter the ge-
netic code. In this reviewwe have reported the alterations of signiﬁcant
sialylated structures and/or the level of expression of their cognate
sialyltransferases, ﬁnding not always consistent results. This may
depend on the fact that in many studies the level of glycosyltransferase
expressionwas inferred from that of the correspondingRNA, although it
is known that the RNA/protein quantitative relationship could be poor.
Moreover, multiple mechanisms contribute to determine the actual
level of a sialylated structure, including masking by substituents, com-
petition between glycosyltransferases and role of sialidases. Ampliﬁca-
tion loops fueled by sialylated molecules which we discuss in this
review are reminiscent of other ampliﬁcation loops described in tumors,
like that originated by Src, ErbB2 and PEAK1, recently described in pan-
creatic cancer [235]. The self-fueling loops where aberrant sialylated
structures sustain cancer growth make sialyltransferases and/or their
products attractive targets for innovative therapeutic treatments. How-
ever, based on experimental evidences, the use of sialyltransferase in-
hibitors or sialidases appears not sufﬁciently speciﬁc for clinical
application, at the moment. More detailed knowledge of the mecha-
nisms linking sialylation and cellular transformation,which is necessary
to warrant the success of therapeutic approaches, will be the focus of
future investigations.
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